Tarsus Pharmaceuticals, Inc.

TARSNASDAQHealthcareBiotechnology

$68.20- (-)1Y +5.50%

As of Oct 23, 2026 close

Market cap: $2.96B
P/E (TTM): -
Forward P/E: -
Dividend yield: -
52-week range: $53.89$91.53
Volume (live): -
Avg. volume (3M): 908.08K

Tarsus Pharmaceuticals, Inc. (TARS) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Tarsus Pharmaceuticals, Inc. stock.

Analyst Consensus Rating

Investment consensus from 9 professional research analysts

Consensus Rating

Buy

Based on 9 unique analysts

(13 total ratings in last 90 days)

Medium Confidence∞:1 Buy/Sell

Average Price Target

$100.88

+47.92% upside

Loading chart...

Strong Sell

Sell

Hold

Buy

Strong Buy

Latest TARS Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Date	Analyst	Firm	Action	Rating	Price Target
Oct 12, 2026	Jenna Davidner	Barclays	Maintains	Buy	$110.00
Oct 12, 2026	Jason Gerberry	BofA Securities	Maintains	Buy	$84.00
Oct 9, 2026	Jenna Davidner	Barclays	Reiterates	Buy	$110.00
Oct 2, 2026	Mazahir Alimohamed	Oppenheimer	Maintains	Buy	$100.00
Sep 24, 2026	Andrea Newkirk	Goldman Sachs	Initiates	Buy	$116.00
Sep 16, 2026	Jenna Davidner	Barclays	Initiates	Buy	$110.00
Sep 8, 2026	Dennis Ding	Jefferies	Reiterates	Buy	$105.00
Aug 12, 2026	Lachlan Hanbury Brown	William Blair	Maintains	Buy	-
Aug 12, 2026	Graig Suvannavejh	Mizuho	Maintains	Buy	$100.00
Aug 11, 2026	Graig Suvannavejh	Mizuho	Maintains	Buy	$100.00
Aug 8, 2026	Francois Brisebois	LifeSci Capital	Initiates Coverage	Buy	$104.00
Aug 7, 2026	Francois Brisebois	LifeSci Capital	Reiterates	Buy	$104.00
Aug 7, 2026	Matthew Caufield	HC Wainwright	Reiterates	Buy	$88.00

Jenna Davidner

Barclays

BuyMaintains

$110.00

Oct 12

Jason Gerberry

BofA Securities

BuyMaintains

$84.00

Oct 12

Jenna Davidner

Barclays

BuyReiterates

$110.00

Oct 9

Mazahir Alimohamed

Oppenheimer

BuyMaintains

$100.00

Oct 2

Andrea Newkirk

Goldman Sachs

BuyInitiates

$116.00

Sep 24

Jenna Davidner

Barclays

BuyInitiates

$110.00

Sep 16

Dennis Ding

Jefferies

BuyReiterates

$105.00

Sep 8

Lachlan Hanbury Brown

William Blair

BuyMaintains

Aug 12

Graig Suvannavejh

Mizuho

BuyMaintains

$100.00

Aug 12

Graig Suvannavejh

Mizuho

BuyMaintains

$100.00

Aug 11

Francois Brisebois

LifeSci Capital

BuyInitiates Coverage

$104.00

Aug 8

Francois Brisebois

LifeSci Capital

BuyReiterates

$104.00

Aug 7

Matthew Caufield

HC Wainwright

BuyReiterates

$88.00

Aug 7

Source: Professional analyst ratings and price targets from the last 90 days. Data as of Oct 12, 2026. Data sources and methodology

Frequently Asked Questions

What is the analyst consensus rating for TARS?

The analyst consensus rating for TARS is Buy, based on the latest ratings from 9 analysts over the last 90 days.

What is the average price target for TARS?

The average 12-month price target for TARS is $100.88, representing an upside of 47.9% from the Oct 23, 2026 close of $68.20.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.